0001562180-24-000484.txt : 20240117 0001562180-24-000484.hdr.sgml : 20240117 20240117160154 ACCESSION NUMBER: 0001562180-24-000484 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240116 FILED AS OF DATE: 20240117 DATE AS OF CHANGE: 20240117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reine Allan CENTRAL INDEX KEY: 0001714023 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39634 FILM NUMBER: 24538389 MAIL ADDRESS: STREET 1: C/O PIERIS PHARMACEUTICALS, INC. STREET 2: 255 STATE STREET CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foghorn Therapeutics Inc. CENTRAL INDEX KEY: 0001822462 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-586-3100 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-01-16 true 0001822462 Foghorn Therapeutics Inc. FHTX 0001714023 Reine Allan 500 TECHNOLOGY SQUARE STE #700 CAMBRIDGE MA 02139 false true false false Chief Financial Officer false Common Stock 53784.00 D Stock Options (Right to buy) 3.72 2029-09-16 Common Stock 257513.00 257513.00 D Stock Option (right to buy) 8.77 2030-08-17 Common Stock 91891.00 91891.00 D Stock Option (right to buy) 16.63 2031-01-27 Common Stock 120000.00 120000.00 D Stock Option (right to buy) 14.87 2032-01-25 Common Stock 135000.00 135000.00 D Stock Option (right to buy) 8.38 2033-01-25 Common Stock 90000.00 90000.00 D The option vested as to 25% of the underlying shares of common stock on September 17, 2020, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vested as to 25% of the underlying shares of common stock on August 18, 2021, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Exit Form 4 filed solely to report the Reporting Person is no longer an officer of the Issuer within the meaning of Rule 16a-1 of the Securities Exchange Act of 1934, as amended. /s /Adrian Gottschalk, Attorney-in-Fact for Allan Reine 2024-01-17